In a landmark development for the field of regenerative medicine, Cellino Biotech, Inc. has been awarded up to $25 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), a division within the U.S. Department of Health and Human Services. This grant will significantly advance Cellino’s NEBULA, a cutting-edge biomanufacturing technology designed to produce personalized regenerative medicines on an unprecedented scale.
The NEBULA project marks the inaugural venture supported by ARPA-H’s Scalable Solutions Mission Office under its Open Broad Agency Announcement. The technology promises to transform the production of personalized regenerative cells, particularly induced pluripotent stem cells (iPSCs), by enabling scalable, autonomous, and high-precision manufacturing. This innovation is poised to address a broad range of chronic conditions, including Parkinson’s disease, heart disease, spinal cord injuries, age-related macular degeneration, and diabetes, impacting over 50 million Americans.
Dr. Nabiha Saklayen, CEO & Co-Founder of Cellino, expressed enthusiasm about the new funding. “At Cellino, our mission is to revolutionize the treatment of humanity’s most challenging diseases through advanced biomanufacturing technology. This support from ARPA-H is crucial for accelerating our efforts to bring potentially curative cell therapies to patients nationwide and globally,” she stated.
Matthias Wagner, CTO & Co-Founder, echoed this sentiment, emphasizing the importance of the grant. “We are excited to advance our AI-driven biomanufacturing technology with ARPA-H’s support. Our goal is to make ‘Your cells, your cure’ a reality by significantly enhancing the scalability and precision of cell and tissue production.”
Jason Roos, Ph.D., Director of ARPA-H’s Scalable Solutions Mission Office, highlighted the broader implications of the grant. “Developing novel therapies is just one part of the equation. Scaling the manufacturing process to ensure affordability and accessibility is equally critical. ARPA-H is committed to fostering innovations that can achieve both.”
Cellino’s proprietary biomanufacturing approach integrates AI-guided, laser-based processes to minimize variability and enhance the consistency of cell and tissue products. This technology is designed to reduce costs and improve the accessibility of personalized regenerative medicines through the use of patient-specific closed cassettes.
Editorial Opinion:
Cellino Biotech’s recent achievement underscores a pivotal shift in the landscape of regenerative medicine. The substantial funding from ARPA-H not only validates Cellino’s innovative approach but also positions the company as a frontrunner in personalized medicine. By leveraging advanced biomanufacturing technologies and artificial intelligence, Cellino is addressing two of the most pressing challenges in healthcare today: scalability and personalization.
The company’s focus on creating ultra-scalable, autonomous biomanufacturing systems could significantly reduce the costs associated with regenerative therapies, making these treatments more accessible to a broader segment of the population. As we see a growing emphasis on personalized medicine, Cellino’s advancements hold the promise of transforming patient care and outcomes across a wide array of conditions.
Furthermore, Cellino’s commitment to minimizing immune-related complications and improving health equity aligns with the broader goals of modern medicine. By obviating the need for donor matches and enhancing the precision of cell therapies, Cellino is not just innovating but is actively working towards a future where personalized regenerative medicine becomes a standard rather than an exception.
For further details or corrections, please reach out to editor@thetimesmag.com.
